Menu

Pooling Consumer Genetic Data, Researchers ID Links to Depression

Access to data from thousands of genotyping customers helped scientists detect novel associations with the disorder across the genome.

Aug 2, 2016
Alison F. Takemura

FLICKR, DANI LURIEThe genetic underpinnings of depression have remained frustratingly elusive. But by scanning the genomes of hundreds of thousands of individuals, a team has located 15 genomic sites implicated in depression among people of European descent. The group reported its findings yesterday (August 1) in Nature Genetics.

“It’s a markedly better step than I believe anybody has taken before,” Patrick Sullivan, a geneticist who studies depression at the University of North Carolina, Chapel Hill, told STAT News.

The team, led by researchers at Pfizer, utilized a trove of genotyping data from the direct-to-consumer genetics company 23andMe, whose customers can opt to make their results—including medical history questionnaires—anonymously available to researchers. The team scanned the genomes of more than 141,000 people of European ancestry who had been diagnosed with depression as well as those of more than 330,000 healthy controls. While the majority of the data came from 23andMe’s database, some was derived from a prior genome-wide association study (GWAS) led by the Psychiatric Genomic Consortium, the National Institutes of Health (NIH) noted in a statement.

There are likely hundreds of genes involved in the etiology of depression. Each one’s effect is so small that it takes a huge sample sizes to detect them. “Everyone is recognizing that this is a numbers problem,” study coauthor Ashley Winslow, who was formerly a neuroscientist at Pfizer and is now the director of neurogenetics at the Orphan Disease Center at the University of Pennsylvania, told MIT Technology Review.

The genomic regions the team homed in on are involved in “regulating gene expression and the birth of new neurons in the developing brain,” according to the NIH.

“We hope these findings help people understand that depression is a brain disease, with its own biology,” study coauthor Roy Perlis of Massachusetts General Hospital, said in the NIH statement. “Now comes the hard work of using these new insights to try to develop better treatments.”

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the target cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway.